Using p53 to help diagnose ovarian cancer

South Asian Journal of Cancer

Volumn 1, Issue 2, 2012, Pages 56-57

  Bansal, Shweta ^a  

^a SL Raheja Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; FAS ANTIGEN; PROTEIN; PROTEIN P21; PROTEIN P53; PROTEIN PIDD; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER STAGING; CARCINOGENESIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG TARGETING; EDITORIAL; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENE; OVARY CANCER; PATHOGENESIS; PREMATURE AGING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 84886493000     PISSN: 2278330X     EISSN: 22784306     Source Type: Journal    
DOI: 10.4103/2278-330X.103708     Document Type: Editorial

References (4)

1. Choudhary M, Goyal S, Pujani M, et al . A cytohistological study of p53 over expression in ovarian neoplasms. South Asian J Cancer 2012; 2: 58-61.
2. Bode AM. Too much of a good thing? Trends Endocrinol Metab 2002;13:139-40.
3. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002;2:594-604.
4. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, et al. p53 mutant mice that display early ageingassociated phenotypes. Nature 2002;415:45-53.